Artielle ImmunoTherapeutics develops biologics that redirect neuroimmune inflammation for patients with multiple sclerosis, stroke, and treatment-resistant cancers.
Artielle ImmunoTherapeutics grew out of research at Oregon Health & Science University and the VA Portland Healthcare System into a drug developer built on the DRhQ platform, molecules derived from an MHC II fragment tethered to a myelin peptide. Its lead molecule inhibits macrophage migration inhibitory factor signaling through the CD74 receptor on monocytes and inflammatory T cells, reversing the chemotactic gradient that draws those cells to sites of central nervous system injury. The company is advancing the platform toward clinical trials in neuroinflammatory disease and cancer.
Artielle's competitive focus is DRhQ's dual action on the MIF/CD74 pathway, positioned against the sparse alternatives in its target indications: no approved pharmacotherapy for methamphetamine use disorder, a single approved drug for ischemic stroke, and few remaining options for cancers that resist existing immunotherapies. It targets patients with secondary-progressive multiple sclerosis, substance use disorder, stroke, and treatment-resistant melanoma or triple-negative breast cancer.
Artielle ImmunoTherapeutics' most recent funding round was for $185.7k (USD) in April 2010.
As of Apr 13, 2010, Artielle ImmunoTherapeutics has disclosed funding of $11.2M (USD).

Artin Bioscience
artinbio.com

Artax Biopharma
artaxbiopharma.com

Artiva Biotherapeutics
artivabio.com
ImmunArtes

Artbio
artbio.com

Artiam Bio
artiambio.net

Allterum Therapeutics
allterum.com

Macrophage Therapeutics
macrophagetx.com

Artios Pharma
artios.com

Aptabridge
aptabridge.com

Aristea Therapeutics
aristeatx.com
DecImmune Therapeutics
decimmune.com

Innox
innoxpharma.com

Arete Therapeutics

MindImmune Therapeutics
mindimmune.com

IMMvention Therapeutix

ImmunoMind
ImmuRx
immurx.com

Allorion Therapeutics
alloriontx.com

PIPr Therapeutics